The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
Open accessAbstract
PURPOSE: To provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management. METHODS: We used data from 3,184 BRCA1 and 2,157 BRCA2 families in the Consortium of Investigators of Modifiers of BRCA1/2 to estimate age-specific relative (RR) and absolute risks for 22 first primary cancer types adjusting for family ascertainment. RESULTS: BRCA1 PVs were associated with risks of male breast (RR = 4.30; 95% CI, 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach (RR = 2.17; 95% CI, 1.25 to 3.77) cancers. Associations with colorectal and gallbladder cancers were also suggested. BRCA2 PVs were associated with risks of male breast (RR = 44.0; 95% CI, 21.3 to 90.9), stomach (RR = 3.69; 95% CI, 2.40 to 5.67), pancreatic (RR = 3.34; 95% CI, 2.21 to 5.06), and prostate (RR = 2.22; 95% CI, 1.63 to 3.03) cancers. The stomach cancer RR was higher for females than males (6.89 v 2.76; P = .04). The absolute risks to age 80 years ranged from 0.4% for male breast cancer to approximately 2.5% for pancreatic cancer for BRCA1 carriers and from approximately 2.5% for pancreatic cancer to 27% for prostate cancer for BRCA2 carriers. CONCLUSION: In addition to female breast and ovarian cancers, BRCA1 and BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, and prostate (only BRCA2 PVs) cancers, but not with the risks of other previously suggested cancers. The estimated age-specific risks will refine cancer risk management in men and women with BRCA1/2 PVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Self-citationThe Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Self-citationCancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationCancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Self-citationA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Self-citationPrograms for pedigree analysis: Mendel, Fisher, and dGene
Lange, K., Weeks, D., Boehnke, M., MacCluer, J. W., & MacCluer, J. W. (1988) · Genetic Epidemiology · doi:10.1002/gepi.1370050611 · Cited by 616
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
Antoniou, A. C., Cunningham, A. P., Peto, J., Evans, D. G., Lalloo, F., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Southey, M. C., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604305 · Cited by 525
Self-citationVariation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers
Thompson, D., & Easton, D. (2001) · The American Journal of Human Genetics · doi:10.1086/318181 · Cited by 489
Self-citationBreast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers
Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm203 · Cited by 430
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 420
Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 399
Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/513891 · Cited by 387
Self-citationRisk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F., & Evans, D. G. R. (2012) · Familial Cancer · doi:10.1007/s10689-011-9506-2 · Cited by 307
Self-citationGermline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Kerber, R. A., & Slattery, M. L. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009259 · Cited by 279
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Nyberg, T., Frost, D., Barrowdale, D., Evans, D. G., Bancroft, E., Adlard, J., Ahmed, M., Barwell, J., Brady, A. F., Brewer, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.08.025 · Cited by 248
Self-citationAscertainment in the sequential sampling of pedigrees
Cannings, C., & Thompson, E. A. (1977) · Clinical Genetics · doi:10.1111/j.1399-0004.1977.tb00928.x · Cited by 241
Validation of family history data in cancer family registries
Ziogas, A., & Anton-Culver, H. (2003) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(02)00593-7 · Cited by 240
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. F., Offit, K., & Robson, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5546 · Cited by 206
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Stadler, Z. K., Maio, A., Chakravarty, D., Kemel, Y. M., Sheehan, M. R., Salo‐Mullen, E. E., Tkachuk, K. A., Fong, C. J., Nguyen, B., Erakky, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03661 · Cited by 175
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0604 · Cited by 165
CIMBA, Chenevix-Trench, G., Milne, R. L., Antoniou, A. C., Couch, F. J., Easton, D. F., & Goldgar, D. E. (2007) · Breast Cancer Research · doi:10.1186/bcr1670 · Cited by 163
Self-citationOh, M., Alkhushaym, N., Fallatah, S., Althagafi, A. A., Aljadeed, R., Alsowaida, Y. S., Jeter, J., Martin, J. R., Babiker, H. M., McBride, A., et al. (2019) · The Prostate · doi:10.1002/pros.23795 · Cited by 151
Associations of High-Grade Prostate Cancer withBRCA1andBRCA2Founder Mutations
Agalliu, I., Gern, R. W., Leanza, S. M., & Burk, R. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1822 · Cited by 147
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
the Hereditary Breast Cancer Study Group, Phelan, C. M., Iqbal, J., Lynch, H. T., Lubiński, J., Gronwald, J., Møller, P., Ghadirian, P., Foulkes, W. D., Armel, S. R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.741 · Cited by 139
Self-citationMilne, R. L., Osório, A., y Cajal, T. R., Vega, A. I., Llort, G., de la Hoya, M., Díez, O., Alonso, M. C., Lázaro, C., Blanco, I., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4436 · Cited by 131
Self-citationA resolution of the ascertainment sampling problem I. Theory
Ewens, W. J., & Shute, N. C. E. (1986) · Theoretical Population Biology · doi:10.1016/0040-5809(86)90042-0 · Cited by 114
Silvestri, V., Leslie, G., Barnes, D. R., and the CIMBA Group, Agnarsson, B. A., Aittomäki, K., Alducci, E., Andrulis, I. L., Barkardottir, R. B., Barroso, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2134 · Cited by 69
Self-citationPARP inhibitors in gastric cancer: beacon of hope
Wang, Y., Zheng, K., Huang, Y., Xiong, H., Su, J., Chen, R., & Zou, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02005-6 · Cited by 61
Cited by
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 512
Kratzer, T. B., Bandi, P., Freedman, N. D., Smith, R. A., Travis, W. D., Jemal, A., & Siegel, R. L. (2024) · Cancer · doi:10.1002/cncr.35128 · Cited by 512
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Sessa, C., Balmaña, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., Domchek, S. M., Evans, D. G., Fischerova, D., Harbeck, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.004 · Cited by 295
Self-citationHelicobacter pylori , Homologous-Recombination Genes, and Gastric Cancer
Usui, Y., Taniyama, Y., Endo, M., Koyanagi, Y. N., Kasugai, Y., Oze, I., Ito, H., Imoto, I., Tanaka, T., Tajika, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211807 · Cited by 254
Self-citation
Metadata
- Authors
- Li, S., Silvestri, V., Leslie, G., Rebbeck, T. R., Neuhausen, S. L., Hopper, J. L., Nielsen, H. R., Lee, A., Yang, X., McGuffog, L., Parsons, M. T., Andrulis, I. L., Arnold, N., Belotti, M., Borg, Å., Buecher, B., Buys, S. S., Caputo, S. M., Chung, W. K., Colas, C., Colonna, S. V., Cook, J., Daly, M. B., de la Hoya, M., de Pauw, A., Delhomelle, H., Eason, J., Engel, C., Evans, D. G., Faust, U., Fehm, T. N., Fostira, F., Fountzilas, G., Frone, M., Garcia-Barberan, V., Garre, P., Gauthier-Villars, M., Gehrig, A., Glendon, G., Goldgar, D. E., Golmard, L., Greene, M. H., Hahnen, E., Hamann, U., Hanson, H., Hassan, T., Hentschel, J., Horvath, J., Izatt, L., Janavicius, R., Jiao, Y., John, E. M., Karlan, B. Y., Kim, S.-W., Konstantopoulou, I., Kwong, A., Laugé, A., Lee, J. W., Lesueur, F., Mebirouk, N., Meindl, A., Mouret-Fourme, E., Musgrave, H., Ngeow Yuen Yie, J., Niederacher, D., Park, S. K., Pedersen, I. S., Ramser, J., Ramus, S. J., Rantala, J., Rashid, M. U., Reichl, F., Ritter, J., Rump, A., Santamariña, M., Saule, C., Schmidt, G., Schmutzler, R. K., Senter, L., Shariff, S., Singer, C. F., Southey, M. C., Stoppa-Lyonnet, D., Sutter, C., Tan, Y., Teo, S. H., Terry, M. B., Thomassen, M., Tischkowitz, M., Toland, A. E., Torres, D., Vega, A., Wagner, S. A., Wang-Gohrke, S., Wappenschmidt, B., Weber, B. H. F., Yannoukakos, D., Spurdle, A. B., Easton, D. F., Chenevix-Trench, G., Ottini, L., & Antoniou, A. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-05-10
- Volume
- 40
- Issue
- 14
- Pages
- 1529-1541
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3216620312
- Cited by
- 287
- References
- 35
- FWCI
- 31.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.